Dr. Marty Makary has been removed from his position as FDA commissioner, a decision announced by President Donald Trump. This change follows a period of controversy surrounding Makary's leadership, particularly regarding the FDA's handling of the Covid pandemic and regulatory decisions that faced criticism from various stakeholders, including drugmakers and patient advocacy groups.
Reports indicate that Makary's resignation was anticipated, as the White House had been considering his dismissal due to perceived slow progress on key initiatives, such as the legalization of flavored vapes. Kyle Diamantas, the former top food official at the FDA, will serve as the acting commissioner.
Makary's tenure, which lasted over a year, was characterized by internal strife and declining morale among FDA staff, exacerbated by layoffs and the departure of key scientists. His leadership style and decisions, including the rejection of certain drug treatments, led to significant backlash from the biotech and pharmaceutical industries.
Notably, the FDA's initial refusal to review Moderna's flu shot and the rejection of a Huntington's disease gene therapy were particularly contentious. Despite these challenges, Makary defended his record, emphasizing his commitment to the agency's scientific integrity.
The ongoing scrutiny of the FDA's regulatory processes has prompted investigations, including one announced by Senator Ron Johnson into the agency's treatment of rare disease therapies